A multicenter, retrospective, prospective, non-intervention study was conducted to observe the molecular responses in patients with polycythemia vera and essential thrombocythemia with JAK2V617F mutation treated with pegylated interferon a-2b at different dose intensities

A multicenter, retrospective, prospective, non-intervention study was conducted to observe the molecular responses in patients with polycythemia vera and essential thrombocythemia with JAK2V617F mutation treated with pegylated interferon a-2b at different dose intensities - Molecular responses in patients with PV/ET treated with different doses intensities of pegylated interferon a-2b

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065811

Enrollment

Unknown

Registered

2022-11-15

Start date

2022-11-07

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myeloproliferative neoplasms

Interventions

Case series:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with polycythemia vera (PV) or essential thrombocythemia (ET) with JAK2V617F mutation diagnosed according to the World Health Organization (WHO) 2016 criteria; 2. The patient met the indications for interferon therapy and was expected to be treated with pegylated interferon a-2b injection; 3. Patients with polycythemia vera/essential thrombocythemia were treated with pegylated interferon alfa-2b injection by the time of study entry and had at least baseline, 6-month traceability data on JAK2V617F mutation VAF.

Exclusion criteria

Exclusion criteria: 1. Concomitant use of Chinese herbal medicine during treatment is expected/has been anticipated; 2. Retrospective cases had any disease that could affect the evaluation of efficacy, including but not limited to post-polycythemia vera myelofibrosis (PPV-MF) or any non-PV myeloproliferative neoplasm (MPN); 3. Retrospective cases had participated in any interventional clinical study during the study period.

Design outcomes

Primary

Measure	Time frame
JAK2V617F VAF;	—

Countries

China

Contacts

Public ContactMinghui Duan

Department of Hematology, Peking Union Medical College Hospital

mhduan@sina.com+86 69155029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026